Atlas Trials

Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Japanese Male and Female Subjects With Schizophrenia in 2 Parts (Part 1 and 2).

Clinical trial NCT03370640 · COMPLETED

Trial details

NCT number
NCT03370640
Sponsor
Sumitomo Pharma Co., Ltd.
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Schizophrenia
Start date
2017-11-29
Primary completion
2018-09-20
Enrollment
24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.